EUVIMEDEUVIMED entdecken
Crossref

SARS ‐ CoV ‐2‐Specific Antibodies in Pediatric Solid Organ Transplant Recipients: Benefits of Additional Vaccine Doses

Amanda L Adler, Alpana Waghmare, Jodi Smith iD, Megan Kelton, Jane A Dickerson, Jonathan C Reed, Alexander L Greninger, Leanne Kehoe, Tarayn Fairlie, Melissa Briggs Hagen, Claire M Midgley, Kirsten Lacombe und 1 weitere

Pediatric Transplantation · 2025

DOI: 10.1111/petr.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Amanda L Adler und 12 weiteren Autor:innen. Beteiligte Einrichtung: Seattle Children's Research Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CDC HHS, Seattle Children's Foundation, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data are available regarding the development and durability of immune responses following COVID‐19 infection or vaccination in pediatric solid‐organ transplant (SOT) recipients.

Methods

Renal, liver, or intestinal transplant recipients < 21 years of age followed at Seattle Children's Hospital were enrolled from August 2020 to May 2021. Blood samples were collected at ~6‐month intervals for up to 3 years and tested for antinucleocapsid (N) antibodies. COVID‐19 vaccination data were collected from the Washington State Immunization Information System and/or the medical record. Semi‐quantitative anti‐S IgG testing was performed on all postvaccine samples using the Abbott Architect platform. We further evaluated a subset of postvaccine samples using variant‐specific quantitative binding (Meso Scale Discovery, MSD) immunoassays and pseudovirus‐neutralization assays. Antibody levels were compared over time and by vaccine category.

Results

We followed 83 SOT recipients for a median of 12.5 months (IQR 7.0, 28.3). Overall, 16 (19.3%) participants had evidence of SARS‐CoV‐2 infection based on anti‐N antibody detection. Forty‐six (55%) participants had a blood sample collected > 14 days after receipt of a vaccination. Serum IgG to spike antigens (anti‐S antibody) increased following vaccination and increased with the number of vaccine doses received as assessed by both the Abbott and MSD assays. Neutralizing activity was significantly lower against the Omicron subvariants compared to the ancestral strain.

Conclusion

Pediatric SOT recipients demonstrated strong antibody responses following SARS‐CoV‐2 vaccination, with higher anti‐S antibody responses following > 2 doses of vaccine. Our study offers unique longitudinal immune response data in this vulnerable patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2Organ TransplantationTransplant RecipientsHumansChildMaleFemaleChild, PreschoolAdolescentInfantImmunoglobulin GVaccinationYoung Adult

Stichwörter der Autor:innen

antibodiesimmunizationpediatric transplantation

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Seattle Children's Research Institute, Seattle, Washington, USA.
  • Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

ORCID-Profile: Jodi Smith, Janet A Englund

Förderung

  • CDC HHS
  • Seattle Children's Foundation
  • Centers for Disease Control and Prevention

Zitieren

APA

Adler, A. L., Waghmare, A., Smith, J., Kelton, M., Dickerson, J. A., Reed, J. C., Greninger, A. L., Kehoe, L., Fairlie, T., Hagen, M. B., Midgley, C. M., Lacombe, K., & Englund, J. A. (2025). SARS ‐ CoV ‐2‐Specific Antibodies in Pediatric Solid Organ Transplant Recipients: Benefits of Additional Vaccine Doses. Pediatric Transplantation. https://doi.org/10.1111/petr.70050

Vancouver

Adler AL, Waghmare A, Smith J, Kelton M, Dickerson JA, Reed JC, et al. SARS ‐ CoV ‐2‐Specific Antibodies in Pediatric Solid Organ Transplant Recipients: Benefits of Additional Vaccine Doses. Pediatric Transplantation. 2025. doi:10.1111/petr.70050

BibTeX
@article{Adler2025,
  author = {Adler, Amanda L and Waghmare, Alpana and Smith, Jodi and Kelton, Megan and Dickerson, Jane A and Reed, Jonathan C and Greninger, Alexander L and Kehoe, Leanne and Fairlie, Tarayn and Hagen, Melissa Briggs and Midgley, Claire M and Lacombe, Kirsten and Englund, Janet A},
  title = {SARS ‐ CoV ‐2‐Specific Antibodies in Pediatric Solid Organ Transplant Recipients: Benefits of Additional Vaccine Doses},
  journal = {Pediatric Transplantation},
  year = {2025},
  doi = {10.1111/petr.70050}
}
Kostenlos starten →